- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02921685
Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (PIRAT)
A Phase 1 Study of MONALIZUMAB (IPH2201), a Humanized Anti CD94/NKG2A Monoclonal Antibody (Mab) Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (SCT) Prepared With a Reduced Intensity Conditioning
Study Overview
Detailed Description
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative option for most of hematological malignancies, though the graft-versus-tumor (GVT) effect mediated by immune cells from the donor. However, the use of Allo-HSCT is limited by its toxicity, notably the graft-versus-host disease (GVHD) that is a major cause of non-relapse mortality (NRM). Conditioning regimens dramatically improved during the last fifteen years, with a decrease of both GVHD and NRM rates. Now, disease recurrence after Allo-HSCT is the first cause of treatment failure and remains a concern for approximately 30% of the patients.
Based on a safety immunologic platform (ATG based reduced toxicity conditioning regimens), it is needed to develop post Allo-HSCT strategies to decrease the incidence of relapse. In this context, the modulation of immune cell activity could play a role to prevent relapse. NK cells have a unique capacity to exert potent GVT effects without inducing GVHD. Moreover, NK cells recovery occurs early after Allo-HSCT and NK cells function are not severely impaired by the use of ciclosporin A, that is given for few months after Allo-HSCT as GVHD prophylaxis. Thus, NK cell modulation appears as a viable option for early immune intervention after Allo-HSCT.
Monalizumab (IPH2201), a monoclonal antibody has a non-depleting and purely blocking activity directed with high affinity and specificity against the CD94/NKG2A receptor expressed by subsets of NK cells, activated αβ CD8+ T cells, γδ-T cells and NK T cells. By suppressing the inhibitory signal transduced by NKG2A, IPH2201 enhances the anti-tumor functions, including cytolytic activity of these immune effector cells.The aim of the study is to determine the safety of IPH2201 after allogenic stem cell transplantation.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Bouches Du Rhônes
-
Marseille, Bouches Du Rhônes, France, 13009
- Recruiting
- Institut Paoli Calmettes
-
Contact:
- Dominique GENRE, MD
- Phone Number: 33 4 91 22 37 78
- Email: genred@ipc.unicancer.fr
-
Contact:
- Isabelle BOQUET, PhD
- Phone Number: 33 4 91 22 37 78
- Email: boqueti@ipc.unicancer.fr
-
Sub-Investigator:
- Raynier DEVILLIER, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients presenting a hematological malignancy (acute myeloid leukemia, acute lymphoblastic leukemia, High risk R-IPSS myelodysplastic syndromes, multiple myeloma, chronic lymphoid leukemia, chronic myeloid leukemia, myeloproliferative neoplasm, Hodgkin lymphoma or Non-Hodgkin lymphoma) treated by allogeneic HSCT according to the following parameters :
- Donor : HLA matched related or unrelated (10/10) donor
- Graft : peripheral blood stem cells
- Conditioning : All types of conditioning reduced toxicity conditioning regimens ATG as in-vivo T-cell depletion
- GVHD prophylaxis by cyclosporine, still ongoing at full dose at the time of the inclusion
Patient being in one of the following post-graft situation at the time of inclusion:
- Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) patients: in morphological complete remission (CR) with less than 5% bone marrow blast count.
- High risk R-IPSS myelodysplastic syndromes patients: with at least marrow CR with less than 5% marrow blast count.
- Multiple myeloma patients: in at least very good partial response.
- Chronic Lymphoid Leukemia patients: in CR.
- Chronic Myeloid Leukemia patients: in hematological CR.
- Myeloproliferative neoplasm patients: no criteria for disease in acceleration phase.
- Hodgkin lymphoma or Non-Hodgkin lymphoma patients: in CR.
- Age ≥ 18 and ≤ 70 years
- ECOG = 0-1 or Karnofsky index ≥ 70%
Clinical laboratory values at screening
- Calculated creatinine clearance (according to MDRD) > 50 ml/min/1.73 m2
- Independence of red blood cell transfusion
- Platelet count > 75 x 109/l
- ANC > 1 x 109/l
- Bilirubin < 1.5 ULN
- ALT and AST < 3 ULN
- Patients (male or female) who accept and are able to use contraceptive methods recognized as highly effective throughout the study and up to 5 months after the drug administration
- Signed informed consent of the current clinical study, prior to any protocol-specific procedure
- Patient affiliated to the national "Social Security" regimen or beneficiary of this regimen
Non inclusion Criteria:
- Previous history of grade ≥ II acute GVHD (Glucksberg classification)
- Current active disease or positive serology for HIV before grafting, and/or HCV with detectable viremia and/ or HBV with positive Hbs Antigen.
Abnormal cardiac status with any of the following :
- Ejection fraction (measured by ultrasound or radionuclide imaging) < 50%
- Unstable angina
- Myocardial infarction within the last 6 months
- Presence or persistence of documented congestive heart failure (New York Heart Association functional classification III-IV)
- Arrhythmia requiring treatment and which is not stabilized by the treatment.
- QTc ≥ 450 ms (M) or 470 ms (F) (Bazett formula)
- Previous other allogeneic hematopoietic transplantation or solid organ transplantation
- Any other serious concurrent uncontrolled medical disorder within 4 weeks prior to IPH2201 administration
- Use of systemic corticosteroids ongoing or within the last 1 week prior IPH2201 admin-istration
- Use of any investigational agent within 3 months prior to first dosing (except procedure of conditioning regimen including registered drugs combinations, i.e. Busulfan and Fludarabine or Busulfan and Endoxan)
- History of another malignancy (except, basal cell carcinoma of the skin, or in situ cervix carcinoma, or any other malignancy in complete remission for more than 3 years since the completion of the treatment). However in the case of leukemia or MDS a previous malignancy accountable for the present disease will not be an exclusion criteria if in complete remission for more than 2 years
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- Pregnant or lactating women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Monalizumab
Monalizumab treatment will be initiated 75 to 100 days after hematopoietic stem cells transplantation.
Patients will receive a single dose of monalizumab by intravenous route over 1 hour.
|
Four dose levels will be tested.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurence ratio of dose-limiting toxicity (DLT)
Time Frame: 4 weeks
|
The occurrence of any of these 3 events will lead to the reporting of a Dose Limiting Toxicity:
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of acute GVHD of each grade or chronic GVHD of each degree of severity
Time Frame: from D0 to Week 26 after administration of IPH2201 and at 1 year after transplantation
|
Safety will be assessed using Glucksberg's classification for acute Graft versus host disease (GVHD) and NIH classification for chronic GVHD.
|
from D0 to Week 26 after administration of IPH2201 and at 1 year after transplantation
|
Probabilities of non-relapse mortality (NRM)
Time Frame: 1 year after the administration of IPH2201
|
1 year after the administration of IPH2201
|
|
Cumulative incidence of relapse (CIR)
Time Frame: 1 year after administration of IPH2201.
|
Efficacy endpoint
|
1 year after administration of IPH2201.
|
Probability of Disease Free Survival (DFS)
Time Frame: 1 year after the administration of IPH2201
|
Efficacy endpoint
|
1 year after the administration of IPH2201
|
Probability of Overall survival (OS)
Time Frame: 1 year after the administration of IPH2201
|
Efficacy endpoint
|
1 year after the administration of IPH2201
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Didier BLAISE, MD, PhD, Institut Paoli-Calmettes
Publications and helpful links
General Publications
- Ruggeri L, Urbani E, Andre P, Mancusi A, Tosti A, Topini F, Blery M, Animobono L, Romagne F, Wagtmann N, Velardi A. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica. 2016 May;101(5):626-33. doi: 10.3324/haematol.2015.135301. Epub 2015 Dec 31.
- Godal R, Bachanova V, Gleason M, McCullar V, Yun GH, Cooley S, Verneris MR, McGlave PB, Miller JS. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant. 2010 May;16(5):612-21. doi: 10.1016/j.bbmt.2010.01.019. Epub 2010 Feb 6.
- Rathmann S, Glatzel S, Schonberg K, Uhrberg M, Follo M, Schulz-Huotari C, Kaymer M, Veelken H, Finke J, Fisch P. Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010 Apr;16(4):469-81. doi: 10.1016/j.bbmt.2009.12.008. Epub 2010 Jan 4.
- Pical-Izard C, Crocchiolo R, Granjeaud S, Kochbati E, Just-Landi S, Chabannon C, Frassati C, Picard C, Blaise D, Olive D, Fauriat C. Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome. Biol Blood Marrow Transplant. 2015 Mar;21(3):429-39. doi: 10.1016/j.bbmt.2014.11.681. Epub 2015 Jan 9.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PIRAT-IPC 2015-018
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancies
-
Cooperative Study Group A for HematologyCompletedHEMATOLOGIC MALIGNANCIESKorea, Republic of
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Medical College of WisconsinCompletedMalignancies, HematologicUnited States
-
Sinocelltech Ltd.RecruitingRelapsed or Refractory Hematologic MalignanciesChina
-
Vanda PharmaceuticalsUnknownRelapsed or Refractory Hematologic MalignanciesUnited States
-
Washington University School of MedicineRecruitingPediatric Hematologic MalignanciesUnited States
-
Precision BioSciences, Inc.RecruitingHematologic Malignancy | CD19 Expressing MalignanciesUnited States
-
Constellation PharmaceuticalsNot yet recruitingSolid Tumor | Hematologic Malignancy | Advanced Malignancies
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingAdvanced Solid Tumors and Hematologic MalignanciesChina
-
Suzhou Junjing BioSciences Co., Ltd.RecruitingAdvanced Solid Tumors | Advanced Hematologic MalignanciesChina
Clinical Trials on Monalizumab
-
Innate PharmaTerminatedChronic Lymphocytic LeukemiaUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingMSI | dMMR Colorectal CancerFrance
-
The Netherlands Cancer InstituteAstraZenecaActive, not recruitingBreast CancerNetherlands
-
MedImmune LLCCompletedStage III Non-small Cell Lung Cancer | UnresectableUnited States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
-
AstraZenecaRecruitingNon-Small Cell Lung CancerChina, Australia, Korea, Republic of, Canada, Poland, Spain, Vietnam, Germany, Brazil, Italy, Japan, Taiwan, Thailand, United States, United Kingdom, Portugal, Turkey, France, Peru, Colombia, Russian Federation, Ukraine
-
Innate PharmaAstraZenecaCompletedHead and Neck NeoplasmsUnited States, France
-
AstraZenecaInnate PharmaActive, not recruitingSquamous Cell Carcinoma of the Head and NeckUnited States, France, Italy, Spain, Belgium, Canada, Taiwan, Switzerland, Korea, Republic of, Japan, Poland, Russian Federation, United Kingdom, Austria, Brazil, Germany, Netherlands, Portugal, Australia, Philippines, Bulgaria, G... and more
-
MedImmune LLCCompletedNSCLC | Resectable | Early-stageUnited States, Canada, Switzerland, Italy, France, Portugal, Spain
-
Centre Leon BerardCompletedSARS-CoV-2 (COVID-19) Infection | Advanced or Metastatic Hematological or Solid TumorFrance
-
Assistance Publique Hopitaux De MarseilleActive, not recruitingNon-small Cell Lung CancerFrance